Scandion Oncology explores potential new treatments of cancer drug resistance using cellular screening assays and tools through the DEN50-R platform.
The platform allows for screening in non-resistant and resistant cancer cells simultaneously, providing unprecedented insights into cancer drug resistance mechanisms in a streamlined fashion. Scandion Oncology holds a high number of different model systems built upon this platform allowing for a broad screening of potential new treatments across different cancers and cancer therapies.
